

Europäisches
Patentamt

European Patent
Office

Office européen
des brevets

Rec'd PCT/PTO 29 JUN 2004
PCT/EP 02/00002

REC'D 17 MAR 2003

WIPO

PCT



Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten internationalen Patentanmeldung überein.

The attached documents are exact copies of the international patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet international spécifiée à la page suivante.

Den Haag, den
The Hague,
La Haye, le

12 MAR 2003

Der Präsident des Europäischen Patentamts
Im Auftrag
For the President of the European Patent Office
Le Président de l'Office européen des brevets
p. o.

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

C.A.J.A. PASCHE

Patentanmeldung Nr.
Patent application no.
Demande de brevet n°

PCT/EP 02/00002

BEST AVAILABLE COPY

**Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation**



Anmeldung Nr.:
Application no.: PCT/EP 02/00002
Demande n°:

Anmelder:
Applicant(s): 1. ACTELION PHARMACEUTICALS LTD - Allschwil, Switzerland
Demandeur(s):

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention: NOVEL ALKANSULFONAMIDES

Anmeldetag:
Date of filing:
Date de dépôt: 02 January 2002 (02.01.2002)

In Anspruch genommene Priorität(en)
Priority(ies) claimed
Priorité(s) revendiquée(s)

Staat:	Tag:	Aktenzeichen:
State:	Date:	File no.
Pays:	Date:	Numéro de dépôt:

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)
Designation of contracting states : See Form PCT/RO/101 (enclosed)
Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

Bemerkungen:
Remarks:
Remarques:

PCT REQUEST

Actel 22/E11

Original (for SUBMISSION) - printed on 27.12.2001 10:06:54 AM

III-3	Applicant and/or inventor	
III-3-1	This person is:	inventor only
III-3-4	Name (LAST, First)	CLOZEL, Martine
III-3-5	Address:	Winterhalde 3b CH-4102 Binningen Switzerland
III-4	Applicant and/or inventor	
III-4-1	This person is:	inventor only
III-4-4	Name (LAST, First)	WELLER, Thomas
III-4-5	Address:	Hoelzlistrasse 58 CH-4102 Binningen Switzerland
III-5	Applicant and/or inventor	
III-5-1	This person is:	inventor only
III-5-4	Name (LAST, First)	FISCHLI, Walter
III-5-5	Address:	ACTELION Pharmaceuticals Ltd. Obertorweg 64 CH-4123 Allschwil Switzerland
IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	HOFMANN, Dieter
IV-1-2	Address:	StratAll Therwilerstrasse 87 CH-4153 Reinach Switzerland
IV-1-3	Telephone No.	+41 61 713 1560
IV-1-4	Facsimile No.	+41 61 713 1561
IV-1-5	e-mail	hofmannndrd@bluewin.ch
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR and any other State which is a Contracting State of the European Patent Convention and of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	--

Actelion 22/E11

NOVEL ALKANSULFONAMIDES

5 Introduction:

The present invention relates to novel alkanesulfonamides of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for
10 the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.

Endothelins (ET-1, ET-2, and ET-3) are 21-amino acid peptides produced and
15 active in almost all tissues (Yanagisawa M et al.: Nature (1988) 332:411). Endothelins are potent vasoconstrictors and important mediators of cardiac, renal, endocrine and immune functions (McMillen MA et al.: J Am Coll Surg (1995) 180:621). They participate in bronchoconstriction and regulate neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and cell
20 differentiation (Rubanyi GM et al.: Pharmacol Rev (1994) 46:328).

Two endothelin receptors have been cloned and characterized in mammals (ET_A, ET_B) (Arai H et al.: Nature (1990) 348:730; Sakurai T et al.: Nature (1990) 348:732). The ET_A receptor is characterized by higher affinity for ET-1 and ET-2 than for ET-3.
25 It is predominant in vascular smooth muscle cells and mediates vasoconstricting and proliferative responses (Ohlstein EH et al.: Drug Dev Res (1993) 29:108). In contrast, the ET_B receptor has equivalent affinity for the three endothelin isopeptides and binds the linear form of endothelin, tetra-ala-endothelin, and sarafotoxin S6C (Ogawa Y et al.: BBRC (1991) 178:248). This receptor is located in the vascular
30 endothelium and smooth muscles, and is also particularly abundant in lung and

brain. The ET_B receptor from endothelial cells mediates transient vasodilator responses to ET-1 and ET-3 through the release of nitric oxide and/or prostacyclin whereas the ET_B receptor from smooth muscle cells exerts vasoconstricting actions (Sumner MJ et al.: Brit J Pharmacol (1992) 107:858). ET_A and ET_B receptors are
5 highly similar in structure and belong to the superfamily of G-protein coupled receptors.

A pathophysiological role has been suggested for ET-1 in view of its increased plasma and tissue levels in several disease states such as hypertension, pulmonary
10 hypertension, sepsis, atherosclerosis, acute myocardial infarction, congestive heart failure, renal failure, migraine and asthma. As a consequence, endothelin receptor antagonists have been studied extensively as potential therapeutic agents. Endothelin receptor antagonists have demonstrated preclinical and/or clinical efficacy in various diseases such as cerebral vasospasm following subarachnoid
15 hemorrhage, heart failure, pulmonary and systemic hypertension, neurogenic inflammation, renal failure and myocardial infarction.

Today, only one endothelin receptor antagonist (bosentan, TracleerTM) is marketed and several are in clinical trials. However, some of these molecules possess a
20 number of weaknesses such as complex synthesis, low solubility, high molecular weight, poor pharmacokinetics, or safety problems (e.g. liver enzyme increases). Furthermore, the contribution of differing ET_A / ET_B receptor blockade to the clinical outcome is not known. Thus, tailoring of the physicochemical and pharmacokinetic properties and the selectivity profile of each antagonist for a given clinical indication
25 is mandatory. So far, no endothelin receptor antagonists with a pyrimidine core structure containing an n-alkanesulfonamide unit attached to the 4-position of the core pyrimidine have been reported [2, 3, 5, 6, 8]. We have discovered a new class of substituted pyrimidines of the general formula I below and found that they allow the specific tailoring described above.

In addition, compounds exhibiting mixed as well as ET_A-selective binding profiles have been identified.

The inhibitory activity of the compounds of general formula I on endothelin receptors can be demonstrated using the test procedures described hereinafter:

For the evaluation of the potency and efficacy of the compounds of the general formula I the following tests were used:

1) Inhibition of endothelin binding to membranes from CHO cells carrying human ET receptors:

For competition binding studies, membranes of CHO cells expressing human recombinant ET_A or ET_B receptors were used. Microsomal membranes from recombinant CHO cells were prepared and the binding assay was carried out as previously described (Breu V., et al, FEBS Lett 1993; 334:210).

The assay was performed in 200 μ L 50 mM Tris/HCl buffer, pH 7.4, including 25 mM MnCl₂, 1 mM EDTA and 0.5% (w/v) BSA in polypropylene microtiter plates. Membranes containing 0.5 μ g protein were incubated for 2 h at 20°C with 8 pM [¹²⁵I]ET-1 (4000 cpm) and increasing concentrations of unlabelled antagonists. Maximum and minimum binding were estimated in samples without and with 100 nM ET-1, respectively. After 2 h, the membranes were filtered on filterplates containing GF/C filters (Unifilterplates from Canberra Packard S.A. Zürich, Switzerland). To each well, 50 μ L of scintillation cocktail was added (MicroScint 20, Canberra Packard S.A. Zürich, Switzerland) and the filter plates counted in a microplate counter (TopCount, Canberra Packard S.A. Zürich, Switzerland).

All the test compounds were dissolved, diluted and added in DMSO. The assay was run in the presence of 2.5% DMSO which was found not to interfere significantly with the binding. IC₅₀ was calculated as the concentration of antagonist inhibiting 50 % of the specific binding of ET-1. For reference compounds, the following IC₅₀

values were found: *ET_A* cells: 0.075 nM (n=8) for ET-1 and 118 nM (n=8) for ET-3;
ET_B cells: 0.067 nM (n=8) for ET-1 and 0.092 nM (n=3) for ET-3.

The IC₅₀ values obtained with compounds of general formula I are given in Table 1.

5

Table 1:

Compound of Example	IC ₅₀ [nM]	
	ET _A	ET _B
Example 1	3.96	>1000
Example 2	5.99	989
Example 3	38.2	>1000
Example 4	6.34	>1000
Example 5	3.6	>1000
Example 6	17.1	>1000
Example 7	16.3	367
Example 8	11	549
Example 9	5.2	187
Example 10	42.6	689
Example 11	5.3	59
Example 12	59	469

2) Inhibition of endothelin-induced contractions on isolated rat aortic rings (ET_A receptors) and rat tracheal rings (ET_B receptors):

The functional inhibitory potency of the endothelin antagonists was assessed by their inhibition of the contraction induced by endothelin-1 on rat aortic rings (ET_A receptors) and of the contraction induced by sarafotoxin S6c on rat tracheal rings (ET_B receptors). Adult Wistar rats were anesthetized and exsanguinated. The thoracic aorta or trachea were excised, dissected and cut into rings of 3-5 mm length. The endothelium/epithelium was removed by gentle rubbing of the intimal surface. Each ring was suspended in a 10 ml isolated organ bath filled with Krebs-Henseleit solution (in mM; NaCl 115, KCl 4.7, MgSO₄ 1.2, KH₂PO₄ 1.5, NaHCO₃ 25, CaCl₂ 2.5, glucose 10) kept at 37°C and gassed with 95% O₂ and 5% CO₂. The rings were connected to force transducers and isometric tension was recorded (EMKA Technologies SA, Paris, France). The rings were stretched to a resting tension of 3 g (aorta) or 2 g (trachea). Cumulative doses of ET-1 (aorta) or sarafotoxin S6c (trachea) were added after a 10 min incubation with the test compound or its vehicle. The functional inhibitory potency of the test compound was assessed by calculating the concentration ratio, i.e. the shift to the right of the EC₅₀ induced by different concentrations of test compound. EC₅₀ is the concentration of endothelin needed to get a half-maximal contraction, pA₂ is the negative logarithm of the antagonist concentration which induces a two-fold shift in the EC₅₀ value.


Because of their ability to inhibit the endothelin binding, the described compounds can be used for treatment of diseases, which are associated with an increase in vasoconstriction, proliferation or inflammation due to endothelin. Examples of such diseases are hypertension, pulmonary hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, Raynaud's syndrome and portal hypertension. They can also be used in the treatment or prevention of atherosclerosis, restenosis after balloon or stent angioplasty, inflammation, stomach and duodenal ulcer, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, hyperlipidemia as well as other diseases, presently known to be related to endothelin.

The compounds can be administered orally, rectally, parenterally, e.g. by intravenous, intramuscular, subcutaneous, intrathecal or transdermal administration or sublingually or as ophthalmic preparation or administered as aerosol. Examples of applications are capsules, tablets, orally administered suspensions or solutions, suppositories, injections, eye-drops, ointments or aerosols/nebulizers.

Preferred applications are intravenous, intra-muscular, or oral administrations as well as eye drops. The dosage used depends upon the type of the specific active ingredient, the age and the requirements of the patient and the kind of application. Generally, dosages of 0.1 – 50 mg / kg body weight per day are considered. The preparations with compounds can contain inert or as well pharmacodynamically active excipients. Tablets or granules, for example, could contain a number of binding agents, filling excipients, carrier substances or diluents.

Description of the Invention:

The invention consists of the compounds described in **general formula I** and their use as endothelin receptor antagonists and especially their use as medicaments for the treatment and prevention of diseases related to the endothelin system:



General Formula I

wherein

10 **R¹** represents lower alkyl;

R² represents aryl; heteroaryl; lower alkyl;

R³ represents aryl; heteroaryl;

15

R⁴ represents hydrogen; trifluoromethyl; lower alkyl; lower alkyl-amino; lower alkoxy; lower alkoxy-lower alkoxy; hydroxy-lower alkoxy; lower alkyl-sulfinyl; lower alkylthio; lower alkylthio-lower alkyl; hydroxy-lower alkyl; lower alkoxy-lower alkyl; hydroxy-lower alkoxy-lower alkyl; hydroxy-lower alkyl-amino; lower alkyl-amino-lower alkyl; amino; di-lower alkyl-amino; [N-(hydroxy-lower alkyl)-N-(lower alkyl)]-amino; aryl; 20 aryl-amino; aryl-lower alkyl-amino; aryl-thio; aryl-lower alkyl-thio; aryloxy; aryl-lower alkoxy; aryl-lower alkyl; aryl-sulfinyl; heteroaryl; heteroaryl-oxy; heteroaryl-lower alkyl-oxy; heteroaryl-amino; heteroaryl-lower alkyl-amino; heteroaryl-thio; heteroaryl-lower alkyl-thio; heteroaryl-lower alkyl; heteroaryl-sulfinyl; heterocyclyl; 25 heterocyclyl-lower alkoxy; heterocyclyl-oxy; heterocyclyl-amino; heterocyclyl-lower

alkyl-amino; heterocyclyl-thio; heterocyclyl-lower alkyl-thio; heterocyclyl-lower alkyl; heterocyclyl-sulfinyl; cycloalkyl; cycloalkyl-oxy; cycloalkyl-lower alkoxy; cycloalkyl-amino; cycloalkyl-lower alkyl-amino; cycloalkyl-thio; cycloalkyl-lower alkyl-thio; cycloalkyl-lower alkyl; cycloalkyl-sulfinyl;

5

X represents oxygen; a bond;

Y represents oxygen; -NH-; -NH-SO₂-; -NH-SO₂-NH-; -O-CO-NH-; -NH-CO-O-; -NH-CO-NH-;

10

Z represents oxygen; sulfur; -NH-;

n represents an integer selected from 2; 3; 4;

15 and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

In the definitions of the general formula I – if not otherwise stated – the expression
 20 lower means straight and branched chain groups with one to seven carbon atoms, preferably 1 to 4 carbon atoms. Examples of lower alkyl and lower alkoxy groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, hexyl, heptyl, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, sec.-butoxy and tert.-butoxy. Lower alkylendioxy-groups are preferably methylen-dioxy
 25 and ethylen-dioxy groups. Examples of lower alkanoyl-groups are acetyl, propanoyl and butanoyl. Lower alkenylen means e.g. vinylen, propenylen and butenylen. Lower alkenyl and lower alkynyl means groups like ethenyl, propenyl, butenyl, 2-methyl-propenyl, and ethinyl, propinyl, butinyl, pentinyl, 2-methyl-pentinyl. Lower alkenyloxy means allyloxy, vinyloxy and propenyloxy. The expression **cycloalkyl** means a
 30 saturated cyclic hydrocarbon ring with 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, which may be substituted with

lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, and lower alkoxy-lower alkyl groups. The expression **heterocyclyl** means saturated or unsaturated (but not aromatic), four, five-, six- or seven-membered rings containing one or two nitrogen, oxygen or sulfur atoms which may be the same or different and which rings may be adequately substituted with lower alkyl, lower alkoxy, e.g. piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyranyl, dihydropyranyl, 1,4-dioxanyl, pyrrolidinyl, tetrahydrofuranyl, dihydropyrrolyl, dihydroimidazolyl, dihydropyrazolyl, pyrazolidinyl and substituted derivatives of such rings with substituents as outlined above. The expression **heteroaryl** means six-membered aromatic rings containing one to four nitrogen atoms, benzofused six-membered aromatic rings containing one to three nitrogen atoms, five-membered aromatic rings containing one oxygen or one nitrogen or one sulfur atom, benzofused five-membered aromatic rings containing one oxygen or one nitrogen or one sulfur atom, five membered aromatic rings containing an oxygen and nitrogen atom and benzo fused derivatives thereof, five-membered aromatic rings containing a sulfur and a nitrogen atom and benzo fused derivatives thereof, five-membered aromatic rings containing two nitrogen atoms and benzo fused derivatives thereof, five membered aromatic rings containing three nitrogen atoms and benzo fused derivatives thereof or the tetrazolyl ring; e.g. furanyl, thienyl, pyrrolyl, pyridinyl, pyrimidinyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, triazinyl, thiazinyl, thiazolyl, isothiazolyl, pyridazinyl, oxazolyl, isoxazolyl, 5-oxo-1,2,4-oxadiazolyl, 5-oxo-1,2,4-thiadiazolyl, 5-thioxo-1,2,4-oxadiazolyl, 2-oxo-1,2,3,5-oxathiadiazolyl, whereby such rings may be substituted with lower alkyl, lower alkenyl, amino, amino-lower alkyl, halogen, hydroxy, lower alkoxy, trifluoromethoxy, trifluoromethyl, carboxyl, carboxamidyl, thioamidyl, amidinyl, lower alkoxy-carbonyl, cyano, hydroxy-lower alkyl, lower alkoxy-lower alkyl or another heteroaryl- or heterocyclyl-ring. The expression **aryl** represents unsubstituted as well as mono-, di- or tri-substituted aromatic rings with 6 to 10 carbon atoms like phenyl or naphthyl rings which may be substituted with aryl, halogen, hydroxy, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkenyloxy, lower alkynyl-lower alkoxy, lower alkenylen, lower alkyleneoxy or lower alkylendioxy forming with the phenyl ring a five- or six-membered ring, hydroxy-

lower alkyl, hydroxy-lower alkenyl, hydroxy-lower alkyl-lower alkynyl, lower alkoxy-lower alkyl, lower alkoxy-lower alkoxy, trifluoromethyl, trifluoromethoxy, cycloalkyl, hydroxy-cycloalkyl, heterocyclyl, heteroaryl.

5 The expression pharmaceutically acceptable salts encompasses either salts with inorganic acids or organic acids like hydrohalogenic acids, e.g. hydrochloric or hydrobromic acid; sulfuric acid, phosphoric acid, nitric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, methanesulfonic acid, p- toluenesulfonic acid and the like or in case the compound of formula I is acidic in nature with an inorganic
10 base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide and the like.

The compounds of the general formula I might have one or more asymmetric carbon atoms and may be prepared in form of optically pure enantiomers or
15 diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and also in the meso-form. The present invention encompasses all these forms. Mixtures may be separated in a manner known per se, i.e. by column chromatography, thin layer chromatography, HPLC or crystallization.

20

Because of their ability to inhibit the endothelin binding, the described compounds of the general formula I and their pharmaceutically acceptable salts may be used for treatment of diseases which are associated with an increase in vasoconstriction, proliferation or inflammation due to endothelin. Examples of such diseases are
25 hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, Raynaud's syndrome, portal hypertension and pulmonary hypertension. They can also be used for the treatment or prevention of atherosclerosis, restenosis after balloon or stent angioplasty, inflammation, stomach
30 and duodenal ulcer, cancer, prostatic hypertrophy, erectile dysfunction, hearing

loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, 5 hyperlipidemia as well as other diseases presently known to be related to endothelin.

These compositions may be administered in enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions, in nasal form like 10 sprays or rectally in form of suppositories. These compounds may also be administered intramuscularly, parenterally or intravenously, e.g. in form of injectable solutions.

These pharmaceutical compositions may contain the compounds of formula I as 15 well as their pharmaceutically acceptable salts in combination with inorganic and/or organic excipients which are usual in the pharmaceutical industry like lactose, maize or derivatives thereof, talcum, stearic acid or salts of these materials.


For gelatine capsules vegetable oils, waxes, fats, liquid or half-liquid polyols may be 20 used. For the preparation of solutions and sirups e.g. water, polyols, saccharose, glucose can be used. Injectables can be prepared by using e.g. water, polyols, alcohols, glycerin, vegetable oils, lecithin or liposomes. Suppositories may be prepared by using natural or hydrogenated oils, waxes, fatty acids (fats), liquid or half-liquid polyols.

25 The compositions may contain in addition preservatives, stability improving substances, viscosity improving or regulating substances, solubility improving substances, sweeteners, dyes, taste improving compounds, salts to change the osmotic pressure, buffer or anti-oxidants.

The compounds of general formula I may also be used in combination with one or more other therapeutically useful substances e.g. α - and β -blockers like phentolamine, phenoxybenzamine, atenolol, propranolol, timolol, metoprolol, carteolol and the like; vasodilators like hydralazine, minoxidil, diazoxide or flosequinan; calcium-antagonists like diltiazem, nicardipine, nimodipine, verapamil or nifedipine; ACE-inhibitors like cilazapril, captopril, enalapril, lisinopril and the like; potassium activators like pinacidil; angiotensin II receptor antagonists like losartan, valsartan, irbesartan and the like; diuretics like hydrochlorothiazide, chlorothiazide, acetolamide, bumetanide, furosemide, metolazone or chlortalidone; sympatholitics like methyldopa, clonidine, guanabenz or reserpine and other therapeutics which serve to treat high blood pressure or any cardiac disorders.

The dosage may vary within wide limits but should be adapted to the specific situation. In general the dosage given daily in oral form should be between about 3 mg and about 3 g, preferably between about 10 mg and about 1 g, especially preferred between 5 mg and 300 mg, per adult with a body weight of about 70 kg. The dosage should be administered preferably in 1 to 3 doses per day which are of equal weight. As usual children should receive lower doses which are adapted to body weight and age.

Preferred compounds are compounds of **formula II**:



Formula II


5 wherein

R¹ represents ethyl; propyl; iso-propyl; butyl;

R² represents aryl; heteroaryl;

10 and **R³**, **R⁴** and **n** are as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

15 Also preferred compounds are compounds of **formula III**:



Formula III

wherein

R^1 represents ethyl; propyl; iso-propyl; butyl;

R^2 represents aryl; heteroaryl;

5


R^4 represents hydrogen; heteroaryl;

10

and R^3 is as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

Another group of preferred compounds, are the compounds of formula IV:

15



Formula IV

wherein

R^1 represents ethyl; propyl; iso-propyl; butyl;


20

R^2 represents aryl; heteroaryl;

R^4 represents hydrogen; heteroaryl;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

- 5 Another group of preferred compounds, are the compounds of formula V:




Formula V

wherein

- 10 R^1 , R^2 , R^3 and R^4 as well as Y, Z and n are as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

- 15 Also preferred compounds are the compounds of formula VI:



Formula VI

wherein

R^1 represents ethyl; propyl; butyl;

R^2 represents aryl; heteroaryl;

5

R^4 represents hydrogen; heteroaryl;

A represents hydrogen; methyl; ethyl; chlorine; bromine;


10

and n represents the integers 2; 3;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

15

Another group of preferred compounds, are the compounds of formula VII:



Formula VII

20

wherein

R^1 represents ethyl; propyl; butyl;

R^2 represents heteroaryl;

A represents methyl; chlorine; bromine;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates
 5 and the meso-forms and pharmaceutically acceptable salts thereof.

Preferred compounds are:

Ethanesulfonic acid {6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide;

10 n-Propanesulfonic acid {6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide;

Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(4-chloro-phenyl)-pyrimidin-4-yl]-amide;

15 n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(4-chloro-phenyl)-pyrimidin-4-yl]-amide;

Ethanesulfonic acid {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;

n-Propanesulfonic acid {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;


20 Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide;

n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide;


25 Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-amide;


Compounds of the **general formula I** of the present invention can be prepared according to the general sequence of reactions retro-synthetically outlined below. For simplicity and clarity reasons sometimes only parts of the synthetic possibilities which lead to compounds of general formula I are described. The literature
5 references given in brackets [] are set forth at the end of this paragraph.


Retro-synthetic scheme:

The sulfonamides and the dichloropyrimidines were prepared according to procedures described in the literature [3], [5], [6], [10].




As a general different synthetic possibility, in certain cases the side-chain should first be prepared (especially when R^2 represents aryl) and only then the whole side chain should be attached to the pyrimidine core.




Retro-synthetic scheme (continued):


G represents a leaving group like alkylsulfonyl, phenylsulfonyl or halogen.

R^4 represents:




Scheme 1: Schematically exemplified synthesis of Examples 1, 2 and 3:




Scheme 2: Schematically exemplified synthesis of Examples 4, 5 and 6:

Scheme 3: Preparation of substituted pyrimidines [9], [10]:



Scheme 4: Preparation of the precursors for the synthesis of compounds of general formula I wherein X represents a bond [5]:



5

In Scheme 4 the symbols R^3 and R^4 represent the same as defined in general formula I above.

References:

- [1] W. Göhring, J. Schildknecht, M. Federspiel; *Chimia*, **1996**, *50*, 538 – 543.
- 5 [2] W. Neidhart, V. Breu, D. Bur, K. Burri, M. Clozel, G. Hirth, M. Müller, H. P. Wessel, H. Ramuz; *Chimia*, **1996**, *50*, 519 – 524 and references cited there.
- [3] W. Neidhart, V. Breu, K. Burri, M. Clozel, G. Hirth, U. Klinkhammer, T. Giller, H. Ramuz; *Bioorg. Med. Chem. Lett.*, **1997**, *7*, 2223 – 2228. R. A. Nugent, S. T. Schlachter, M. J. Murphy, G. J. Cleek, T. J. Poel, D. G. Whishka, D. R. Graber, Y. Yagi, B. J. Keiser, R. A. Olmsted, L. A. Kopta, S. M. Swaney, S. M. Poppe, J. Morris, W. G. Tarpley, R. C. Thomas; *J. Med. Chem.*, **1998**, *41*, 3793 – 3803.
- 10 [4] J. March; *Advanced Organic Chemistry*, 4th Ed., **1994**, p. 499 and references cited there.
- 15 [5] EP 0 743 307 A1; EP 0 658 548 B1; EP 0 959 072 A1 (Tanabe Seiyaku)
- [6] EP 0 633 259 B1; EP 0 526 708 A1; WO 96/19459 (F. Hoffmann-LaRoche)
- 20 [7] for the Synthesis of 5-membered heterocycles see: Y. Kohara et al; *J. Med. Chem.*, **1996**, *39*, 5228 – 5235 and references cited there.
- [8] EP 0 882 719 A1 (Yamanouchi Pharmaceutical Co., Ltd)
- 25 [9] D. G. Crosby, R. V. Berthold; *J. Org. Chem.*, **1960**; *25*; 1916.
- [10] US-4,233,294 , **1980**, (Bayer AG);
- 30 [11] WO 01/17976; WO 01/46156; WO 01/81335; WO 01/81338; (Actelion Pharmaceuticals Ltd)


Examples

The following examples illustrate the invention. All temperatures are stated in °C.

List of Abbreviations:

5		
	CyHex	cyclohexane
	DBU	1,8-diazabicyclo[5.4.0]undec-7-en(1,5-5)
	DCM	dichloromethane
	DIPEA	diisopropylethylamine
10	DMAP	4-dimethylaminopyridine
	DMF	dimethylformamide
	DMSO	dimethylsulfoxide
	EtOAc	ethyl acetate
	Hex	hexane
15	HV	high vacuum conditions
	MCPBA	m-chloroperbenzoic acid
	min	minutes
	rflx	reflux
	rt	room temperature
20	THF	tetrahydrofuran
	t _R	retention time

The following compounds were prepared according to the procedure described above and shown in *Schemes 1 to 4*. All compounds were characterized by ¹H-NMR (300MHz) and occasionally by ¹³C-NMR (75MHz) (Varian Oxford, 300MHz; 25 chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet; m = multiplet), by LC-MS (Waters Micromass; ZMD-platform with ESI-probe with Alliance 2790 HT; Column: 2x30mm, Gromsil ODS4, 3µm, 120A; Gradient: 0 – 100% acetonitril in water, 6 min, with 0.05% formic acid, 30 flow: 0.45ml/min; t_R is given in min.), by TLC (TLC-plates from Merck, Silica gel 60 F₂₅₄) and occasionally by melting point.

Example 1:

- 5 a) At 0°C a solution of diethyl 2-(p-tolyl)-malonate (14.2 g) in methanol (50 ml) was slowly added to a solution of sodium methylate (9.4 g) in methanol (300 ml). Upon completion of the addition the reaction mixture was allowed to warm up and formamidine hydrochloride (5.4 g) was added. The mixture was stirred at rt for 16 h. The solvent was removed under reduced pressure and the remaining residue was
- 10 treated with 2 N hydrochloric acid (150 ml). The suspension was stirred for 0.5 h. At 0-5°C, the pH was carefully adjusted to 4 using 10 N sodium hydroxide solution. The precipitate was collected, washed with cold water, isopropanol, and diethyl ether and dried under high vacuum at 65°C to give 4,6-dihydroxy-5-(p-tolyl)-pyrimidine (11.2 g) (or a tautomer) as a white powder.
- 15 b) At rt N,N-dimethylaniline (10 ml) was added to a mixture of 4,6-dihydroxy-5-(p-tolyl)-pyrimidine (5.1 g) and POCl₃ (75 ml). The reaction mixture was stirred at 70°C for 16 h. The excess of POCl₃ was distilled off and the remaining oil was treated with an ice:water mixture and extracted three times with diethyl ether. The combined
- 20 organic extracts were washed with 1N aqueous hydrochloric acid followed by brine, dried over MgSO₄ and evaporated. The remaining brown oil was crystallised from isopropanol. The pale yellow crystals were collected, washed with cold isopropanol and dried under high vacuum to furnish 4,6-dichloro-5-(p-tolyl)-pyrimidine (4.1 g).

c) Ethanesulfonyl chloride (24 g) was dissolved in THF (30 ml) and cooled to 0°C. Then ammonium hydroxide solution (25%, 40 ml) was added via addition funnel followed by stirring at rt for 1 h. The THF was removed under reduced pressure and the remaining solution was extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo to give ethanesulfonamide (7.2 g) as an oil which was dissolved in MeOH (100 ml) followed by the addition of potassium tert.-butoxide (7.4 g) and stirring for 30 min. The solvent was evaporated and the residue was washed with diethyl ether and dried at HV to give ethanesulfonamide potassium salt (9.7 g) as a white, hygroscopic powder.


d) 4,6-dichloro-5-(p-tolyl)-pyrimidine (717 mg) was dissolved in DMSO (5 ml) and ethanesulfonamide potassium salt (927 mg) was added and stirring continued for 14 h at rt. The solution was poured onto ice/water and acidified by 2 N HCl to pH 3-4. The precipitate was filtered off and washed with water and diethylether to give ethanesulfonic acid (6-chloro-5-p-tolyl-pyrimidin-4-yl)-amide (370 mg) as a white powder. LC-MS: t_R : 4.09, $[M+H]^+$: 312.10.

e) Ethanesulfonic acid (6-chloro-5-p-tolyl-pyrimidin-4-yl)-amide (363 mg) was added to a solution of potassium tert.-butoxide (427 mg) in ethylene glycol (7 ml) and stirred at 100°C for 7 days. The reaction mixture was then poured onto ice/water and extracted with ethyl acetate. The crude product was purified by chromatography over silicagel with DCM / MeOH = 9 / 1 to give ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-p-tolyl-pyrimidin-4-yl]-amide (310 mg) as a white powder. LC-MS: t_R : 3.47, $[M+H]^+$: 338.13.


f) Ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-p-tolyl-pyrimidin-4-yl]-amide (135 mg) was dissolved in THF (15 ml) and sodium hydride (80 mg) was added followed by stirring for 15 min at 50°C. Then 2-chloro-5-bromo-pyrimidine (162 mg) was added and stirring was continued for 8 h at 70 C. The reaction mixture was poured onto ice

water, acidified with solid citric acid and extracted with ethylacetate. The combined organic extracts were dried over magnesium sulfate and the solvent was evaporated. The crude material was purified by plate chromatography with ethyl acetate / hexane = 1 / 2 to give ethanesulfonic acid {6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide (68 mg) as a white powder. LC-MS: t_R : 4.64, $[M+H]^+$: 496.19.

Example 2:




According to the procedure described in Example 1f) ethanesulfonic acid {6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide (73 mg) was prepared by reaction of ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-p-tolyl-pyrimidin-4-yl]-amide (84 mg) with 2-chloro-5-sulfanyl-pyrimidine (130 mg). LC-MS: t_R : 4.55, $[M+H]^+$: 462.24.

Example 3:

- 5 According to the procedure described in Example 1f) ethanesulfonic acid {6-[2-(5-methoxy-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide (65 mg) was prepared by reaction of ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-p-tolyl-pyrimidin-4-yl]-amide (84 mg) with 2-sulfono-5-methoxy-pyrimidine (103 mg). LC-MS: t_R : 4.25, $[M+H]^+$: 446.35.

10

Example 4:

a) n-Propane sulfonyl chloride (20.7 g) was dissolved in THF (40 ml) and cooled to 0°C. Then ammonium hydroxide solution (25%, 40 ml) was added via addition funnel followed by stirring at rt for 1 h. The THF was removed under reduced pressure and the remaining solution was extracted with ethyl acetate. The combined
5 organic extracts were dried over magnesium sulfate and concentrated in vacuo to give n-propane sulfonamide (10.99 g) as an oil which was dissolved in MeOH (100 ml) followed by the addition of potassium tert.-butoxide (10.6 g) and stirring for 30 min. The solvent was evaporated and the residue was triturated with diethyl ether. The white solid was isolated by filtration and dried at HV to give n-
10 propanesulfonamide potassium salt (13.4 g) as a white, hygroscopic powder.


b) To a solution of 4,6-dichloro-5-(p-tolyl)-pyrimidine (Example 1b; 717 mg) in DMSO (5 ml) and n-propanesulfonamide potassium salt (1016 mg) was added. Stirring was continued for 14 h at rt. The solution was poured onto ice/water and
15 acidified by 2 N HCl to pH 3-4. The precipitate was filtered off and washed with water and diethylether to give n-propanesulfonic acid (6-chloro-5-p-tolyl-pyrimidin-4-yl)-amide (765 mg) as a white powder. LC-MS: t_R : 4.44, $[M+H]^+$: 326.13.

c) n-Propanesulfonic acid (6-chloro-5-p-tolyl-pyrimidin-4-yl)-amide (489 mg) was
20 added to a solution of potassium tert.-butoxide (900 mg) in ethylene glycol (10 ml). The solution was stirred at 100°C for 7 days. The reaction mixture was then poured onto ice/water and extracted with ethyl acetate. The crude product was purified by chromatography over silicagel with DCM / MeOH = 9 / 1 to give n-propanesulfonic acid [6-(2-hydroxy-ethoxy)-5-p-tolyl-pyrimidin-4-yl]-amide (390 mg) as a white
25 powder. LC-MS: t_R : 3.76, $[M+H]^+$: 352.13.


d) n-Propanesulfonic acid [6-(2-hydroxy-ethoxy)-5-p-tolyl-pyrimidin-4-yl]-amide (115 mg) was dissolved in THF (15 ml). Sodium hydride (60 mg) was added followed by stirring for 15 min at 50°C. Then 2-chloro-5-bromo-pyrimidine (135 mg) was added
30 and stirring was continued for 8 h at 75°C. The reaction mixture was poured onto ice water, acidified with solid citric acid and extracted with ethyl acetate. The combined

organic extracts were dried over magnesium sulfate, filtered and the solvent was evaporated. The crude material was purified by plate chromatography with diethyl ether to give n-propanesulfonic acid {6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide (65 mg) as a white powder. LC-MS: t_R : 4.91, $[M+H]^+$: 510.13.


Example 5:



n-Propanesulfonic acid [6-(2-hydroxy-ethoxy)-5-p-tolyl-pyrimidin-4-yl]-amide (88 mg) was dissolved in THF (10 ml) and sodium hydride (46 mg) was added followed by stirring for 15 min at 50°C. Then 2-chloro-5-methylsulfanyl-pyrimidine (88 mg) was added and stirring was continued for 8 h at 75°C. The reaction mixture was poured onto ice water, acidified with solid citric acid and extracted with ethylacetate. The combined organic extracts were dried over magnesium sulfate and the solvent was evaporated. The crude material was recrystallized from methanol to give propane-1-sulfonic acid {6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide (64 mg) as a white powder. LC-MS: t_R : 4.82, $[M+H]^+$: 476.29.

Example 6:

- 5 n-Propanesulfonic acid [6-(2-hydroxy-ethoxy)-5-p-tolyl-pyrimidin-4-yl]-amide (115.5 mg) was dissolved in THF (10 ml) and sodium hydride (60 mg) was added followed by stirring for 15 min at 50°C. Then 2-methanesulfonyl-5-methoxy-pyrimidine (138 mg) was added and stirring was continued for 8 h at 75°C. The reaction mixture was poured onto ice water, acidified with solid citric acid and extracted with ethyl
- 10 acetate. The combined organic layers were dried over magnesium sulfate and the solvent was evaporated. The crude material was purified by plate chromatography with diethyl ether to give propane-1-sulfonic acid {6-[2-(5-methoxy-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide (61 mg) as a white powder. LC-MS: t_R : 4.51, $[M+H]^+$: 460.27.


Example 7:

5 a) To a solution of 4,6-dichloro-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl (prepared as described in [6] and [11]) (1.74 g) in DMSO (5 ml) was added ethanesulfonamide potassium salt (1.62 g). Stirring was continued for 10 days at rt. The reaction mixture was poured onto ice/water and acidified by 2N HCl. The precipitate was filtered off, washed with water and dried at HV to give ethanesulfonic acid [6-chloro-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (1.75 g) as a white powder.
 10 LC-MS: t_R : 3.77, $[M+H]^+$: 422.15.

b) To a solution of potassium tert.-butoxide (366.5 mg) in ethylene glycol (5 ml) was added 1,2-dimethoxy ethane (5 ml) and ethanesulfonic acid [6-chloro-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (420 mg). The reaction mixture was heated
 15 to 85°C for 7 days, concentrated in vacuo, poured onto water, acidified by 2N HCl, and extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The precipitated product was washed with diethyl ether, filtered and dried at HV to give ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (400 mg).
 20 LC-MS: t_R : 3.45, $[M+H]^+$: 448.24.

c) Ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (89 mg) was dissolved in THF (10 ml). Sodium hydride (60 mg) and 2-chloro-5-bromo-pyrimidine (100 mg) were added and the mixture was heated to 75°C for 48 h, then poured onto water, acidified with solid citric acid and the precipitate was filtered off. The crude material was purified by crystallization from methanol to give ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (54 mg) as a white powder. LC-MS: t_R : 4.23, $[M+H]^+$: 605.90.

10 Example 8:




a) To a solution of 4,6-dichloro-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl (prepared as described in [6] and [11]) (1.74 g) in DMSO (5 ml) was added n-propanesulfonamide potassium salt (1.77 g). Stirring was continued for 10 days at rt. The reaction mixture was poured onto ice/water and acidified by 2N HCl. The precipitate was filtered off, washed with water and dried at HV to give n-propanesulfonic acid [6-chloro-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (2.17 g) as a white powder. LC-MS: t_R : 4.14, $[M+H]^+$: 434.13.

b) To a solution of potassium tert.-butoxide (366.5 mg) in ethylene glycol (5 ml) was added 1,2-dimethoxy ethane (5 ml) and n-propanesulfonic acid [6-chloro-5-(2-

ethoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (420 mg). The reaction mixture was heated to 85°C for 7 days, concentrated in vacuo, poured onto water, acidified by 2N HCl and extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate and concentrated in vacuo. The precipitated product was washed with diethylether, filtered and dried at HV to give n-propanesulfonic acid [6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (401 mg). LC-MS: t_R : 3.67, $[M+H]^+$: 462.26.

c) n-Propanesulfonic acid [6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (92 mg) was dissolved in THF (10 ml). Sodium hydride (60 mg) and 2-chloro-5-bromo-pyrimidine (85 mg) were added and the mixture was heated to 75 C for 16 h, then poured onto water, acidified with solid citric acid and the precipitate was filtered off. The crude material was purified by crystallization from methanol to give n-propanesulfonic acid [6-[2-(5-bromopyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (54 mg) as a white powder. LC-MS: t_R : 4.44, $[M+H]^+$: 619.77.


Example 9:



n-Propanesulfonic acid [6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (92 mg) was dissolved in THF (6 ml). Sodium hydride (40 mg) and


2-chloro-5-methylsulfanyl-pyrimidine (71 mg) were added and the mixture was heated to 75°C for 6 h, then poured onto water, acidified with solid citric acid and the precipitate was filtered off. The crude material was purified by crystallization from methanol to give n-propanesulfonic acid [6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (61 mg) as a white powder. LC-MS: t_R : 4.37, $[M+H]^+$: 586.19.

Example 10:




10

n-Propanesulfonic acid [6-(2-(5-methoxy-pyrimidin-2-yloxy)-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (92 mg) was dissolved in THF (6 ml). Sodium hydride (40 mg) and 2-chloro-5-methoxy-pyrimidine (92 mg) were added and the mixture was heated to 75°C for 6 h, then poured onto water, acidified with solid citric acid and the precipitate was filtered off. The crude material was purified by crystallization from methanol to give n-propanesulfonic acid [6-[2-(5-methoxy-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (61 mg) as a white powder. LC-MS: t_R : 4.10, $[M+H]^+$: 570.22.

Example 11:


- 5 Ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidin-4-yl]-amide (89 mg) was dissolved in THF (6 ml). Sodium hydride (40 mg) and 2-chloro-5-methylsulfanyl-pyrimidine (71 mg) were added and the mixture was heated to 75°C for 48 h, then poured onto water, acidified with solid citric acid and the precipitate was filtered off. The crude material was purified by crystallization
- 10 from methanol to give ethanesulfonic acid [6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidin-4-yl]-amide (58 mg) as a white powder. LC-MS: t_R : 4.15, $[M+H]^+$: 572.19.








Example 12:

Ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (89 mg) was dissolved in THF (6 ml). Sodium hydride (40 mg) and 2-chloro-5-methoxy-pyrimidine (92 mg) were added and the mixture was heated to 75°C for 46 h, then poured onto water, acidified with solid citric acid and the precipitate was filtered off. The crude material was purified by crystallization from methanol to give ethanesulfonic acid [6-[2-(5-methoxy-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide (61 mg) as a white powder. LC-MS: t_R : 3.87, $[M-H]^+$: 554.02.


According to the procedures described in the Examples 1 to 12 and in the literature [5], [6], [7], [8] and [11] the compounds depicted in the following tables of Examples 13 to 16 can be prepared.

Example 13:




R^1 :	R^4 :	A	Q
H_3C ----	H ----	H ----	Br ----
 ----	H_3C ----	H_3C ----	Cl ----
 ----	 ----	Cl ----	H_3C ----
 ----	 ----	Br ----	H_3CO ----
	 ----		H_3CS ----
	 ----		H ----








Example 14:




R ¹ :	R ⁴ :	R ³ :	Q
H ₃ C----	H-----		Br-----
	H ₃ C-----		Cl-----
			H ₃ C-----
			H ₃ CO-----
			H ₃ CS-----
			H-----

Example 15:




R^1 :	R^4 :	A	Q
H_3C ----	H ----	H ----	Br ----
 ----	H_3C ----	H_3C ----	Cl ----
 ----	 ----	Cl ----	H_3C ----
 ----	 ----	Br ----	H_3CO ----
	 ----		H_3CS ----
	 ----		H ----

Example 16:



R ¹ :	R ⁴ :	R ³ :	Q
H ₃ C----	H-----		Br-----
	H ₃ C-----		Cl-----
			H ₃ C-----
			H ₃ CO-----
			H ₃ CS-----
			H-----

Claims:**1. Compounds of the general formula I****General Formula I**

5

wherein

 R^1 represents lower alkyl; R^2 represents aryl; heteroaryl; lower alkyl;

10

 R^3 represents aryl; heteroaryl;

15

R^4 represents hydrogen; trifluoromethyl; lower alkyl; lower alkyl-amino; lower alkoxy; lower alkoxy-lower alkoxy; hydroxy-lower alkoxy; lower alkyl-sulfinyl; lower alkylthio; lower alkylthio-lower alkyl; hydroxy-lower alkyl; lower alkoxy-lower alkyl; hydroxy-lower alkoxy-lower alkyl; hydroxy-lower alkyl-amino; lower alkyl-amino-lower alkyl; amino; di-lower alkyl-amino; [N-(hydroxy-lower alkyl)-N-(lower alkyl)]-amino; aryl; aryl-amino; aryl-lower alkyl-amino; aryl-thio; aryl-lower alkyl-thio; aryloxy; aryl-lower alkoxy; aryl-lower alkyl; aryl-sulfinyl; heteroaryl; heteroaryl-oxy; heteroaryl-lower alkyl-oxy; heteroaryl-amino; heteroaryl-lower alkyl-amino; heteroaryl-thio; heteroaryl-lower alkyl-thio; heteroaryl-lower alkyl; heteroaryl-sulfinyl; heterocyclyl; heterocyclyl-lower alkoxy; heterocyclyl-oxy; heterocyclyl-amino; heterocyclyl-lower alkyl-amino; heterocyclyl-thio; heterocyclyl-lower alkyl-thio; heterocyclyl-lower alkyl; heterocyclyl-sulfinyl; cycloalkyl; cycloalkyl-oxy; cycloalkyl-lower alkoxy; cycloalkyl-

20

amino; cycloalkyl-lower alkyl-amino; cycloalkyl-thio; cycloalkyl-lower alkyl-thio;
cycloalkyl-lower alkyl; cycloalkyl-sulfinyl;

X represents oxygen; a bond;

5

Y represents oxygen; -NH-; -NH-SO₂-; -NH-SO₂-NH-; -O-CO-NH-; -NH-CO-O-;
-NH-CO-NH-;

Z represents oxygen; sulfur; -NH-;


10

n represents an integer selected from 2; 3; 4;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or
diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates
and the meso-forms and pharmaceutically acceptable salts thereof.

15

2. Compounds of the formula II:



Formula II

20 wherein


R¹ represents ethyl; propyl; iso-propyl; butyl;

R² represents aryl; heteroaryl;

and R^3 , R^4 and n are as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

5

3. Compounds of the formula III:



Formula III

10 wherein

R^1 represents ethyl; propyl; butyl;


R^2 represents aryl; heteroaryl;

15 R^4 represents hydrogen; heteroaryl;

and R^3 is as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and

20 pharmaceutically acceptable salts thereof.

4. Compounds of the formula IV:



Formula IV

wherein

5 R^1 represents ethyl; propyl; iso-propyl; butyl;


R^2 represents aryl; heteroaryl

R^4 represents hydrogen; heteroaryl;

10

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

15 5. Compounds of the formula V




Formula V

wherein

R^1 , R^2 , R^3 and R^4 as well as Y, Z and n are as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

5

6. Compounds of the formula VI:



Formula VI

10 wherein

R^1 represents ethyl; propyl; butyl;

R^2 represents aryl; heteroaryl;

15 R^4 represents hydrogen or heteroaryl;


A represents hydrogen; methyl; ethyl; chlorine; bromine;

and n represents the integers 2; 3;

20

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

25 7. Compounds of the formula VII



Formula VII

wherein

R¹ represents ethyl; propyl; butyl;

R² represents heteroaryl;

A represents methyl; chlorine; bromine;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

8. The compounds selected from claims 1 to 7

n-Propanesulfonic acid {6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide;

Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(4-chloro-phenyl)-pyrimidin-4-yl]-amide;

n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(4-chloro-phenyl)-pyrimidin-4-yl]-amide;

Ethanesulfonic acid {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;

n-Propanesulfonic acid {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;

Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide;

n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide;

5 Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

10 and pharmaceutically acceptable salts thereof.

9. The compound selected from claims 1 to 7

Ethanesulfonic acid {6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide;

15

and pharmaceutically acceptable salts thereof.

10. Pharmaceutical compositions for the treatment of disorders which are associated with a role of endothelin, especially circulatory disorders such as
20 hypertension, pulmonary hypertenison, ischaemia, vasospasm and angina pectoris and proliferative disorders such as cancer, prostate cancer or melanoma carcinoma, containing a compound of any one of claims 1 to 9 and usual carrier materials and adjuvants.

25 11. Pharmaceutical compositions for the treatment of disorders which are associated with a role of endothelin, such as migraine, asthma, hyperlipidemia or inflammatory disorders, containing a compound of any one of claims 1 to 9 and usual carrier materials and adjuvants.

30 12. The compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of disorders which are associated with a role of endothelin, especially

circulatory disorders such as hypertension, pulmonary hypertension, ischaemia, vasospasm, angina pectoris, hyperlipidemia and proliferative disorders such as cancer, prostate cancer or melanoma carcinoma and migraine and inflammatory disorders.

5

13. The compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of disorders which are associated with a role of endothelin, and require blocking both ET_A and ET_B receptors.

10

14. The compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of disorders which are associated with a role of endothelin, and require selective ET_A-receptor blocking for treatment.

15

15. The compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of disorders which are associated with a role of endothelin, and require selective ET_B-receptor blocking for treatment.

20

16. The use of one or more compounds of any one of claims 1 to 9 as active ingredients for the production of pharmaceutical compositions for the treatment of disorders associated with a role of endothelin, especially circulatory disorders such as hypertension, pulmonary hypertension, ischaemia, vasospasm and angina pectoris and proliferative disorders such as cancer prostate cancer or melanoma carcinoma.

25

17. The use of one or more compounds of any one of claims 1 to 9 as active ingredients for the production of pharmaceutical compositions for the treatment of disorders associated with endothelin activities, such as migraine, asthma, hyperlipidemia or inflammatory disorders.

30

18. A process for the manufacture of pharmaceutical compositions for the treatment of disorders associated with a role of endothelin containing one or more compounds

as claimed in any one of claims 1 to 9 as active ingredients which process comprises mixing one or more active ingredients with pharmaceutically acceptable excipients in a manner known per se.

- 5 19. The novel compounds, processes and methods as well as the use of such compounds substantially as described herein before.

Abstract

5 The invention relates to novel alkanesulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists in the treatment and
10 prevention of diseases associated to the endothelin system.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.